Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce that Cancer Research UK Manchester Institute (CRUK MI), has licensed Flare for fresh insights into structure-based drug design.
“Putting easy-to use and visually driven structure-based design software in the hands of our medicinal chemists will empower them to deliver the next generation of cancer therapeutics more efficiently,” says Professor Caroline Springer, Director of the Drug Discovery Unit, CRUK MI. “These tools provide a common interface to further integrate our medicinal and computational chemistry expertise, and we are particularly excited that we will be able to gain immediate feedback on where to optimise the ligand-protein interactions by visually assessing how protein and ligand electrostatics complement each other.”
“Having licensed our ligand-focused applications, Spark™, Forge™ and Torch™, to CRUK MI for a number of years, we are delighted that this leading research institute, has added Flare™ for structure-based design,” says Dr David Bardsley, Commercial Director, Cresset.
| (Image removed) | (Image removed) | (Image removed) |
| Cresset’s innovative Electrostatic Complementarity TM maps and scores provide rapid feedback on new molecule designs. Green: good electrostatic complementarity. Red: electrostatic clash. |
